HomeCompareYGYI vs JNJ

YGYI vs JNJ: Dividend Comparison 2026

YGYI yields 18018.02% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YGYI wins by $18633001307266260992.00M in total portfolio value
10 years
YGYI
YGYI
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full YGYI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — YGYI vs JNJ

📍 YGYI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYGYIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YGYI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YGYI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YGYI
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, YGYI beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YGYI + JNJ for your $10,000?

YGYI: 50%JNJ: 50%
100% JNJ50/50100% YGYI
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

YGYI
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-4.4
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YGYI buys
0
JNJ buys
0
No recent congressional trades found for YGYI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYGYIJNJ
Forward yield18018.02%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$18633001307266260992.00M$30.3K
Annual income after 10y$18,431,768,966,926,280,000,000,000.00$4,689.40
Total dividends collected$18619711198521020416.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: YGYI vs JNJ ($10,000, DRIP)

YearYGYI PortfolioYGYI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,812,502$1,801,801.80$10,592$272.30+$1.80MYGYI
2$307,151,434$305,212,057.22$11,289$357.73+$307.14MYGYI
3$48,667,022,851$48,338,370,816.14$12,123$472.89+$48667.01MYGYI
4$7,210,053,431,136$7,157,979,716,686.14$13,141$629.86+$7210053.42MYGYI
5$998,798,584,418,300$991,083,827,246,983.60$14,408$846.81+$998798584.40MYGYI
6$129,380,351,742,642,780$128,311,637,257,315,230.00$16,021$1,151.60+$129380351742.63MYGYI
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$18,122$1,588.22+$15672057030122.29MYGYI
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$20,930$2,228.20+$1775286122699574.75MYGYI
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$24,792$3,191.91+$188067607794372832.00MYGYI
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$30,274$4,689.40+$18633001307266260992.00MYGYI

YGYI vs JNJ: Complete Analysis 2026

YGYIStock

Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. It operates in three segments: Direct Selling, Commercial Coffee, and Commercial Hemp. The company offers nutritional supplements, gourmet coffee, weight management products, skincare and cosmetics, health and wellness, packaged foods, lifestyle products, pet care, digital products, telecare health services, apparel and fashion accessories, and business lending products. It also produces and sells coffee products under the Café La Rica, Café Alma, Josie's Java House, Javalution Urban Grind, Javalution Daily Grind, and Javalution Royal Roast brands; and produces and markets a line of coffees under the JavaFit brand directly to consumers. In addition, it offers CBD oils from hemp stock. The company sells coffee and equipment to wellness and retirement communities, and various cruise lines and coffee service operators, as well as through distribution network. Youngevity International, Inc. also markets its products through a range of consumer Websites, such as youngevity.com; ygyi.com; heritagemakers.com; hempfx.com; clrroasters.com; cafelarica.com; javalution.com. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013. Youngevity International, Inc. was founded in 1996 and is headquartered in Chula Vista, California.

Full YGYI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this YGYI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YGYI vs SCHDYGYI vs JEPIYGYI vs OYGYI vs KOYGYI vs MAINYGYI vs ABBVYGYI vs MRKYGYI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.